2′-Chlorodeoxyadenosine Effectively Induces Complete Remission in Hairy Cell Leukaemia

References

• Bouroncle, B. A., Wiseman, B. K. and Doan, C. A. (1958). Leukemic reticuloendotheliosis. Blood, 13, 609–630.
   PubMed Web of Science ®Google Scholar
• Catovsky, D., Pettit, J. E., Galton, D. A. G., Spiers, A. S. D. and Harrison, C. V. (1974). Leukaemic reticuloendotheliosis (‘hairy’ cell leukaemia): a distinct clinico-pathological entity. British Journal of Haematology, 26, 9–27.
   PubMed Web of Science ®Google Scholar
• Catovsky, D., Pettit, J. E., Galetto, J., Okos, A. and Galton, D. A. G. (1974). The B-lymphocyte nature of the ‘hairy’ cell of leukaemic reticuloendotheliosis. British Journal of Haematology, 26, 29–37.
   PubMed Web of Science ®Google Scholar
• Haak, H. L., de Man, J. C. H., Hijmans, W. and Speck, B. (1974). Further evidence for the lymphocytic nature of leukaemic reticuloendotheliosis (hairy-cell leukaemia). British Journal of Haematology, 27, 31–38.
   PubMed Web of Science ®Google Scholar
• Jansen, J., Hermans, J., Remme, J., den Ottolander, G. J. and Cardozo, P. L. (1978). Hairy cell leukaemia: clinical features and effect of splenectomy. Scandinavian Journal of Haematology, 21, 60–71.
   PubMedGoogle Scholar
• Golomb, H. M., Catovsky, D. and Golde, D. W. (1978). Hairy cell leukemia: a clinical review based on 71 cases. Annals of Internal Medicine, 89, 677–683.
   PubMed Web of Science ®Google Scholar
• Naeim, F. (1988). Hairy cell leukemia: characteristics of the neoplastic cells. Human Pathology, 19, 375–388.
   PubMed Web of Science ®Google Scholar
• Robbins, B. A., Ellison, D. J., Spinosa, J. C., Carey, C. A., Lukes, R. J., Poppema, S., et al. (1993). Diagnostic application of two-color flow cytometry in 161 cases of hairy cell leukemia. Blood, 82, 1277–1287.
   PubMed Web of Science ®Google Scholar
• Bader, M., Pedemonte-Coira, B. M., Goris, J., Muthusammy, K., Langshultz, D., Patel, H. and Young, Y. (1996). Flow cytometric detection of CD103 helps to distinguish hairy cell leukemia from other neoplastic B-cell lymphoproliferative disorders. American Journal of Clinical Pathology, 106, (Abstr. 4) 403.
   Google Scholar
• Anderson, K. C., Boyd, A. W., Fisher, D. C., Leslie, D., Schlossman, S. F. and Nadler, L. M. (1985). Hairy cell leukemia: a tumor of pre-plasma cells. Blood, 65, 620–629.
   PubMed Web of Science ®Google Scholar
• Vardiman, J. W. and Golomb, H. M. (1984). Autopsy findings in hairy cell leukemia. Seminars in Oncology, 11, 370–380.
   PubMed Web of Science ®Google Scholar
• Burke, J. S., Byme, G. E. Jr. and Rappaport, H. (1974). Hairy cell leukemia (leukemic reticuloendotheliosis). I: A clinical pathologic study of 21 patients. Cancer, 33, 1399–1410.
   PubMed Web of Science ®Google Scholar
• Diez Martin, J. L., Li, C. Y. and Banks, P. M. (1987). Blastic variants of hairy-cell leukemia. American Journal of Clinical Pathology, 87, 576–583.
   PubMed Web of Science ®Google Scholar
• Catovsky, D., O'Brien, M., Melo, J. V., Wardle, J. and Brozovic, M. (1984). Hairy cell leukemia (HCL) variant: an intermediate disease between HCL and B prolymphocytic leukemia. Seminars in Oncology, 11, 362–369.
   PubMed Web of Science ®Google Scholar
• Demeter, J., Pálóczi, K., Lehoczky, D. and Benczúr, M. (1989). Hairy cell leukaemia: observations on natural killer activity in different clinical stages of the disease. British Journal of Haematology, 71, 239–244.
   PubMed Web of Science ®Google Scholar
• Ingoldby, C. J. H., Ackroyd, N., Catovsky, D. and Spencer, J. (1981). Splenectomy for hairy cell leukaemia. Clinical Oncology, 7, 325–331.
   PubMed Web of Science ®Google Scholar
• van Norman, A. S., Nagorney, D. M., Martin, J. K., Phyliky, R. L. and llstrup, D. M. (1986). Splenectomy for hairy cell leukemia: a clinical review of 63 patients. Cancer, 57, 644–648.
   PubMed Web of Science ®Google Scholar
• Jacobs, P., King, H. S., Dent, D. M. and van der Westhuizen, N. (1987). Splenectomy as primary treatment for hairy cell leukaemia. British Journal of Surgery, 74, 1169–1170.
   PubMed Web of Science ®Google Scholar
• Schiffer, C. A. (1991). Interferon studies in the treatment of patients with leukemia. Seminars in Oncology, 18(Suppl. 7), 1–6.
   PubMedGoogle Scholar
• Nielsen, B. and Braide, I. (1992). Three years' continuous low-dose interferon-α treatment of hairy-cell leukaemia: evaluation of response and maintenance dose. European Journal of Haematology, 49, 174–179.
   PubMed Web of Science ®Google Scholar
• Vedantham, S., Gamliel, H. and Golomb, H. M. (1992). Mechanism of interferon action in hairy cell leukemia: a model of effective cancer biotherapy. Cancer Research, 52, 1056–1066.
   PubMed Web of Science ®Google Scholar
• Kraut, E. H., Bouroncle, B. A. and Grever, M. R. (1989). Pentostatin in the treatment of advanced hairy cell leukemia. Journal of Clinical Oncology, 7, 168–172.
   PubMed Web of Science ®Google Scholar
• Kantarjian, H. M., Schachner, J. and Keating, M. J. (1991). Fludarabine therapy in hairy cell leukemia. Cancer, 67, 1291–1293.
   PubMed Web of Science ®Google Scholar
• Saven, A. and Piro, L. D. (1992). Treatment of hairy cell leukemia. Blood, 79, 1111–1120.
   PubMed Web of Science ®Google Scholar
• Piro, L. D., Carrera, C. J., Carson, D. A. and Beutler, E. (1990). Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. New England Journal of Medicine, 322, 1117–1121.
   PubMed Web of Science ®Google Scholar
• Rieux, C., Bastion, Y., Bazin, M., Dumontet, C., Coiffier, B., Felman, P. and Bryon, P. A. (1995). Effectiveness of 2-chlorodeoxyadenosine in nodal and extra haematopoietic localizations in hairy cell leukaemia. European Journal of Haematology, 55, 133–135.
   PubMed Web of Science ®Google Scholar
• Juliusson, G. and Liliemark, J. (1992). Rapid recovery from cytopenia in hairy cell leukemia after treatment with 2-chloro-2′-deoxyadenosine (CdA): relation to opportunistic infections. Blood, 79, 888–894.
   PubMed Web of Science ®Google Scholar
• Kaspers, G. J. L., Veerman, A. J. P., Pieters, R., Van Zantwijk, I., Hählen, K. and Van Wering, E. R. (1995). Drug combination testing in acute lymphoblastic leukemia using the MTT assay. Leukemia Research, 19, 175–181.
   PubMed Web of Science ®Google Scholar
• Hernández-García, M. T., Hernández-Nieto, L., Brito-Barroso, M. L. and González-Brito, M. L. (1993). Bone marrow fibrosis: histomorphometric analysis and interobserver reproducibility of a simple optical method of assessing its intensity. Clinical and Laboratory Haematology, 15, 129–135.
   PubMedGoogle Scholar
• Harris, N. L., Jaffe, E. S., Stein, H., Banks, P. M., Chan, J. K. C., Cleary, M. L., et al. (1994). A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood, 84, 1361–1392.
   PubMed Web of Science ®Google Scholar
• Demeter, J., Schmid, M. and Porzsolt, F. (1995). Observations regarding hairy cell leukemia and chronic lymphocytic leukemia within the proposed new classification of lymphoid neoplasms. Blood, 85, 1972–1973.
   PubMed Web of Science ®Google Scholar
• Sun, T., Dittmar, K., Koduru, P., Susin, M., Teichberg, S. and Brody, J. (1996). Relationship between hairy cell leukemia variant and splenic lymphoma with villous lymphocytes: presentation of a new concept. American Journal of Hematology, 51, 282–288.
   PubMed Web of Science ®Google Scholar
• Janckila, A. J., Cardwell, E. M., Yam, L. T. and Li, C. Y. (1995). Hairy cell identification by immunohistochemistry of tartrate-resistant acid phosphatase. Blood, 85, 2839–2844.
   PubMed Web of Science ®Google Scholar
• A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. (1997). The Non-Hodgkin's Lymphoma Classification Project. Blood, 89, 3909–3918.
   PubMed Web of Science ®Google Scholar
• Tallman, M. S. and Hakimian, D. (1995). Purine nucleoside analogs: emerging roles in indolent lymphoproliferative disorders. Blood, 86, 2463–2474.
   PubMed Web of Science ®Google Scholar
• Seymour, J. F., Kurzrock, R., Freireich, E. J. and Estey, E. H. (1994). 2-chlorodeoxyadenosine induces durable remissions and prolonged suppression of CD4+ lymphocyte counts in patients with hairy cell leukemia. Blood, 83, 2906–2911.
   PubMed Web of Science ®Google Scholar
• Au, W. Y., Klasa, R. J., Gallagher, R., Le, N., Gascoyne, R. D. and Connors, J. M. (1998). Second malignancies in patients with hairy cell leukemia in British Columbia: a 20-year experience. Blood, 92, 1160–1164.
   PubMed Web of Science ®Google Scholar
• Cheson, B. D., Sorensen, J. M., Vena, D. A., Montello, M. J., Barrett, J. A., Damasio, E., et al. (1998). Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine via the Group C protocol mechanism of the National Cancer Institute: a report of 979 patients. Journal of Clinical Oncology, 16, 3007–3015.
   PubMed Web of Science ®Google Scholar
• Saven, A., Burian, C., Koziol, J. A. and Piro, L. D. (1998). Long-term follow-up of patients with hairy cell leukemia after cladribine treatment. Blood, 92, 1918–1926.
   PubMed Web of Science ®Google Scholar